• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

TearLab cuts headcount in restructuring effort

December 22, 2017 By Sarah Faulkner

TearLabTearLab Corp. (OTC:TEAR) is looking to keep its customer base and reduce the company’s cash burn rate with a new business model that will result in people losing their jobs, according to regulatory filings.

The company said that it wants to focus resources on the development of its next-gen TearLab Discovery platform.

TearLab did not report exactly how many employees it will let go, but said it plans to “reduce headcount across its commercial, administrative and technical functions.”

The company expects to incur a charge of $200,000 – $250,000 related to employee severance costs. TearLab added that it will finish instituting most of the new business model by the end of 2017.

The company this year also implemented a 1-for-10 reverse split of its common stock, reducing the total number of authorized shares of common stock from 95 million to 9.5 million.

This year’s restructuring comes almost one year after a different strategic restructuring resulted in the loss of 54 employees as the company pursued positive cash flow.

The reorganization cost the company $300,000, but was expected to save the company $9.4 million compared to its full year 2015.

Earlier that month, TearLab said it would wind down its majority owned subsidiary OcuHub, expecting another $3.5 million reduction in operating expenses for the year.

Filed Under: Diagnostics, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: TearLab

IN CASE YOU MISSED IT

  • BD’s IV catheters plant in Utah marks 70 years
  • Novo taps Nanexa for long-acting obesity injectables with €1.17B pact
  • Abbott partners with Berry Street to add nutrition coaching to Lingo
  • Dexcom CFO to expand into COO role
  • Beta Bionics insulin patch pump scores FDA clearance

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS